摘要
目的:探讨影响多发性骨髓瘤预后的相关因素。方法:对198例多发性骨髓瘤患者的临床特征、实验室指标及治疗方法采用单因素及多因素的方法,分析与预后相关的影响因素。结果:截止到2011年5月,198例患者的中位生存期为29个月,2年生存率为59.2%,5年生存率为8.3%;单因素统计分析显示,年龄、β2-微球蛋白(β2-MG)、血清白蛋白含量、血肌酐、血红蛋白、C反应蛋白、乳酸脱氢酶(LDH),原始幼稚浆细胞比例、血小板计数、尿蛋白阳性、尿本周蛋白阳性、骨病分级、治疗方案、疾病分期与患者预后相关。多因素统计发现,年龄、β2-MG、血清白蛋白含量、血肌酐、C反应蛋白、LDH、疾病分期为独立预后因素。结论:高龄、高β2-MG、高LDH、高C反应蛋白水平、低白蛋白、血肌酐水平高、DS分期Ⅲ期为预后较差。
Objective： To explore the prognosis factors of multiple myeioma. Method： The clinical features,diagnostic results and treatment were analysed by univariate analysis and multivariate analysis. Result： By May 2011, The media survival time was 29 months, the 2 and 5 years survival rates were 59.2% and 8. 3% in 198 patients. Prognostic factors identified by univariate analysis were age, 132 - microglobulin （ 132 - MG ） , albumin, creatinine, hemoglobin, C-reactive protein, lactate dehydrogenase （ LDH） , the amount of bone marrow plasma cells, platelet count, urinary protein, jones protein in urine, skeletal disease stage, treatment and durie salmon stage. Multivariate analysis showed that age, β2- MG, albumin, creatinine, C-reactive protein, LDH, DS stage was indepent prognostic factors. Conclusion： Age, high level of β2 - MG, high level of LDH, high level of C-reactive protein, low level of albumin, high level of creatinine, Ⅲ DS stage are correla- ted to poor prognosis.
出处
《河北医学》
CAS
2012年第6期763-767,共5页
Hebei Medicine
关键词
多发性骨髓瘤
分期
治疗
预后
多因素分析
Multiple myeloma
Stage
Therapy
Prognosis
Multivariate analysis
